Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK2 V617F |
| Therapy | Ruxolitinib + TGX-221 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK2 V617F | Advanced Solid Tumor | sensitive | Ruxolitinib + TGX-221 | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790). | 24251790 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24251790) | Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. | Full reference... |